文献速递妇科

腹腔镜电动粉碎术行子宫切除术女性中使用标本袋的情况

Containment Bag Use Among Women Who Undergo Hysterectomy With Laparoscopic Power Morcellation.
PubMed 文献 · Obstet Gynecol · 2022-08-03

基于Premier医疗数据库2010至2018年67,115例腹腔镜次全子宫切除术患者,分析FDA安全警示前后腹腔镜电动粉碎器和标本袋使用趋势。FDA警示后电动粉碎器使用每季度下降9.5%(RR 0.91,95%CI 0.90-0.91),标本袋使用每季度增加3%(RR 1.03,95%CI 1.02-1.05),但多数电动粉碎术仍未使用标本袋。

要点

  • 电动粉碎器使用从2013年第四季度66.7%降至2018年第二季度13.3%。
  • 标本袋使用从2013年第四季度5.2%升至2018年第二季度15.2%。
  • 使用标本袋者围手术期并发症率4.5%,未使用者3.3%(P=.001)。

核心结论

  • 腹腔镜电动粉碎器的使用随时间下降,标本袋使用在FDA 2014年警示后增加,但大多数使用电动粉碎器的手术仍未使用标本袋。

研究设计与样本

  • 分析Premier医疗数据库中2010至2018年接受腹腔镜次全子宫切除术的患者数据,按是否使用腹腔镜电动粉碎器分层,并分为FDA警示前(2010年第一季度至2014年第一季度)和警示后(2014年第二季度至2018年第二季度),进行中断时间序列分析。

主要发现

  • 在67,115例患者中,电动粉碎器使用从2013年第四季度66.7%降至2018年第二季度13.3%。
  • FDA警示后时期,电动粉碎器使用可能性每季度下降9.5%(RR 0.91,95%CI 0.90-0.91)。
  • 标本袋使用从2013年第四季度5.2%升至2018年第二季度15.2%,FDA警示后时期使用可能性每季度增加3%(RR 1.03,95%CI 1.02-1.05)。
  • 使用电动粉碎器者中,FDA警示前发现子宫癌或肉瘤54例(0.17%),警示后7例(0.12%)(P=.45);标本袋使用在警示前为11.1%,警示后为14.3%(P=.12)。
  • 未使用标本袋者围手术期并发症率为3.3%,使用标本袋者为4.5%(P=.001),aRR 1.35(95%CI 1.12-1.64)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate trends in use of laparoscopic power morcellators in women undergoing minimally invasive hysterectomy and to examine use of containment systems in these patients in relation to safety guidance from the U.S. Food and Drug Administration (FDA). METHODS: We examined data that were recorded in the Premier Healthcare Database from patients who underwent laparoscopic supracervical hysterectomy from 2010 to 2018. Patients were stratified based on use of laparoscopic power morcellators. The cohort was further stratified as either pre-FDA guidance (2010 quarter 1-2014 quarter 1) or post-FDA guidance (2014 quarter 2-2018 quarter 2). Interrupted time series analyses were performed to determine the effect of FDA guidance on the use of laparoscopic power morcellators and containment bags. RESULTS: Among 67,115 patients, laparoscopic power morcellator use decreased from 66.7% in 2013 quarter 4 to 13.3% by 2018 quarter 2. The likelihood of laparoscopic power morcellator use decreased by 9.5% for each quarter elapsed in the post-FDA warning period (risk ratio [RR] 0.91, 95% CI 0.90-0.91). Containment bag use rose from 5.2% in 2013 quarter 4 to 15.2% by 2018 quarter 2. The likelihood of containment bag use increased by 3% for each quarter elapsed in the post-FDA warning period (RR 1.03, 95% CI 1.02-1.05). Among women who had laparoscopic power morcellator use, uterine cancers or sarcomas were identified in 54 (0.17%) before the FDA guidance compared with seven (0.12%) after the guidance ( P =.45). Containment bags were used in 11.1% of women with uterine cancers or sarcomas before the FDA guidance compared with 14.3% after the guidance ( P =.12). The perioperative complication rate was 3.3% among women who had laparoscopic power morcellator use without a containment bag compared with 4.5% ( P =.001) in those with a containment bag (aRR 1.35, 95% CI 1.12-1.64). CONCLUSION: Use of laparoscopic power morcellators has decreased over time. Containment bag use increased after the FDA's 2014 guidance; however, most procedures employing laparoscopic power morcellators are still performed without a containment bag.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Wright JD, Chen L, Melamed A, et al. Containment Bag Use Among Women Who Undergo Hysterectomy With Laparoscopic Power Morcellation. Obstet Gynecol. 2022. PMID: 35926199. doi:10.1097/AOG.0000000000004886

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。